NEW YORK (Dow Jones)--Celgene Corp. (CELG) raised the price for its flagship blood cancer drug Revlimid by about 4.5% in the U.S. last week, bringing its cost to about $85,000 per year.
The pill, mainly used to treat multiple myeloma, is key to Celgene's growth and made up more than half of the Summit, N.J., drug maker's total revenue of $2.7 billion last year.
via online.wsj.com
No comments:
Post a Comment